BMS-986165

BMS-986165 Suppliers list
Company Name: Zhengzhou Anbu Chem Co.,Ltd
Tel: +86-0371-88006763; +8615988602810
Email: sales@anbuchem.com
Products Intro: Product Name:BMS-986165
CAS:1609392-27-9
Purity:98% Package:1KG
Company Name: Hangzhou ICH Biofarm Co., Ltd
Tel: +86-0571-28186870; +undefined8613073685410
Email: sales@ichemie.com
Products Intro: Product Name:Deucravacitinb
CAS:1609392-27-9
Purity:99.0% Package:1kg;|25kg
Company Name: hebei hongtan Biotechnology Co., Ltd
Tel: +86-86-1913198-3935 +8617331935328
Email: sales03@chemcn.cn
Products Intro: Product Name:Deucravacitinib
CAS:1609392-27-9
Purity:99.9% Package:10g;20.00;USD
Company Name: BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Tel: +86-18600796368 +86-18600796368
Email: sales@sjar-tech.com
Products Intro: Product Name:Deucravacitinib
CAS:1609392-27-9
Purity:More Than 99% Package:1g
Company Name: Cangzhou Kangrui Pharma Tech Co. Ltd.,
Tel: +86-18632776803 +86-13833998158
Email: cangzhoukangrui@126.com
Products Intro: Product Name:Deucravacitinib
CAS:1609392-27-9
Purity:98% Package:10g;|100g;|1000g

BMS-986165 manufacturers

  • Deucravacitinib
  • Deucravacitinib pictures
  • $0.00 / 1g
  • 2024-12-25
  • CAS:1609392-27-9
  • Min. Order: 1g
  • Purity: More Than 99%
  • Supply Ability: 50kg/Month
  • BMS-986165 API
  • BMS-986165 API pictures
  • $100.00 / 1KG
  • 2024-12-24
  • CAS:1609392-27-9
  • Min. Order: 1KG
  • Purity: 99.9%
  • Supply Ability: 500
  • Deucravacitinib
  • Deucravacitinib pictures
  • $20.00 / 10g
  • 2024-12-24
  • CAS:1609392-27-9
  • Min. Order: 100g
  • Purity: 99.9%
  • Supply Ability: 1000kg
BMS-986165 Basic information
Uses
Product Name:BMS-986165
Synonyms:Tyk2-IN-4;TYK2-IN-4;BMS986165;BMS-986165;BMS 986165;Deucravacitinib(BMS986165);Deucravacitinib (TYK2-IN-4;6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide;DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Deucravacitinib
CAS:1609392-27-9
MF:C20H22N8O3
MW:422.45
EINECS:
Product Categories:API;APIS;API
Mol File:1609392-27-9.mol
BMS-986165 Structure
BMS-986165 Chemical Properties
storage temp. Store at -20°C
solubility DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
form A crystalline solid
color Off-white to light yellow
Safety Information
MSDS Information
BMS-986165 Usage And Synthesis
UsesBMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.
UsesDeucravacitinib is a tyrosine kinase 2 inhibitor which can be useful in the treatment of systemic lupus erythematosus.
General Description Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.
Pharmacokinetics The crystalline free base form of deucravacitinib exhibited poor aqueous solubility (5.2 μg/mL), which was still acceptable for preclinical studies. It showed moderate half-lives of 4?5 h across species (mouse, dog, and monkey). Excellent exposures and high bioavailability (F > 85%) in mice, dogs, and monkeys were obtained from oral pharmacokinetic studies at a 10 mpk dose. Following oral administration of deucravacitinib, the major metabolite in human plasma was the cyclopropyl carboxamide hydrolytic cleavage product 4 (6-amino-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylpyridazine-3-carboxamide).
Tag:BMS-986165(1609392-27-9) Related Product Information